FrancophonIA/ELRC3.0 huggingface dataset:
English: The European Medicines Agency has waived the obligation to submit the results of studies with MAVENCLAD in all subsets of the paediatric population in multiple sclerosis (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka MAVENCLAD u svim podskupinama pedijatrijske populacije za multiplu sklerozu (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: Non-clinical safety pharmacological and toxicological assessment of cladribine in animal models relevant for the safety assessment of cladribine did not yield significant findings other than those predicted by the pharmacologic mechanism of cladribine.
Croatian: Neklinička sigurnosna farmakološka i toksikološka ocjena kladribina na životinjskim modelima važnima za procjenu sigurnosti kladribina nije polučila značajne nalaze osim onih predviđenih na temelju farmakološkog mehanizma kladribina.
English: Swallow tablet(s) with water.
Croatian: Progutajte tabletu (tablete) s vodom.
English: You do not have to take the tablets at meal times.
Croatian: Ne morate uzimati tablete u vrijeme obroka.
English: Receive counselling before starting the treatment (consisting of two treatment courses administered at the beginning of two consecutive years) both in year 1 and year 2;
Croatian: dobiju savjete prije početka liječenja (koje se sastoji od dva ciklusa liječenja primijenjenih na početku dvije uzastopne godine) i u 1. i u 2. godini liječenja;
English: Cladribine reduces CD19+ B cells and CD16+/CD56+ natural killer cells, which also recover faster than CD4+ T cells.
Croatian: Kladribin smanjuje broj CD19+B stanica i CD16+/CD56+ stanica prirodnih ubojica, koje se također brže oporavljaju nego CD4+ T stanice.
English: The patient's hands must be dry when handling the tablets and washed thoroughly afterwards.
Croatian: Bolesnik mora imati suhe ruke pri rukovanju tabletama i nakon toga ih mora temeljito oprati.
English: Patients with current active malignancies must not receive Mavenclad treatment;
Croatian: bolesnici s trenutno aktivnim zloćudnim bolestima ne smiju primati Mavenclad;
English: You will be given MAVENCLAD as two treatment courses over 2 years.
Croatian: Dobit ćete MAVENCLAD kroz dva ciklusa liječenja tijekom 2 godine.
English: Known BCRP inhibitors, which may alter the pharmacokinetics of BCRP substrates by 20% in vivo, include eltrombopag.
Croatian: Poznati inhibitori BCRP-a, koji mogu promijeniti farmakokinetiku supstrata BCRP-a za 20 % in vivo, uključuju eltrombopag.
English: In the clinical study data base of cladribine in MS (1,976 patients, 8,650 patient years) no case of PML has been reported.
Croatian: U bazi podataka kliničkog ispitivanja kladribina kod MS-a (1976 bolesnika, 8650 bolesnik-godina) nije zabilježen nijedan slučaj PML-a.
English: Pharmacokinetic interactions
Croatian: Farmakokinetičke interakcije
English: You must not receive such vaccines during MAVENCLAD treatment.
Croatian: Ne smijete primati takva cjepiva tijekom liječenja lijekom MAVENCLAD.
English: Patients with lymphocyte counts below 500 cells/mm³ should be actively monitored for signs and symptoms suggestive of infections, in particular herpes zoster.
Croatian: Bolesnike s brojem lifmocita manjim od 500 stanica/mm³ potrebno je aktivno pratiti zbog znakova i simptoma koji ukazuju na infekcije, osobito herpes zoster.
English: Following completion of the 2 treatment courses, no further cladribine treatment is required in years 3 and 4 (see section 5.1).
Croatian: Nakon završetka 2 ciklusa liječenja, nije potrebno daljnje liječenje kladribinom tijekom 3. i 4. godine (vidjeti dio 5.1).
English: Cladribine cumulative dose 3.5 mg/kg (n = 433)
Croatian: Kumulativna doza kladribina 3,5 mg/kg (n = 433)
English: Prior to launch of Mavenclad (cladribine) in each Member State (MS) the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational materials (EM), including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority (NCA).
Croatian: Prije puštanja lijeka Mavenclad (kladribin) u promet, u svakoj zemlji članici nositelj odobrenja za stavljanje lijeka u promet mora se usuglasiti s nacionalnim regulatornim tijelom oko sadržaja i oblika edukacijskih materijala, uključujući načine priopćavanja, modalitete distribucije i sve druge aspekte programa.
English: Do not start MAVENCLAD together with medicines that weaken your immune system or reduce the production of blood cells by your bone marrow.
Croatian: Nemojte početi uzimati MAVENCLAD zajedno s lijekovima koji slabe Vaš imunološki sustav ili smanjuju stvaranje krvnih stanica u koštranoj srži.
English: - The other ingredients are hydroxypropylbetadex, sorbitol and magnesium stearate.
Croatian: - Drugi sastojci su hidroksipropilbetadeks, sorbitol i magnezijev stearat.
English: In hepatic in vitro systems, negligible metabolism of cladribine was observed (at least 90% was unchanged cladribine).
Croatian: U jetrenim sustavima in vitro opažen je zanemariv metabolizam kladribina (najmanje je 90 % bio neizmijenjen kladribin).
English: Such medicines include alemtuzumab, daclizumab, dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta, natalizumab or teriflunomide.
Croatian: Takvi lijekovi uključuju alemtuzumab, daklizumab, dimetilfumarat, fingolimod, glatiramer acetat, interferon beta, natalizumab ili teriflunomid.
English: MAVENCLAD contains hydroxypropylbetadex, which may be available for complex formation with other medicinal products, potentially leading to an increase in bioavailability of such a product (especially medicinal products with low solubility, see section 5.2).
Croatian: MAVENCLAD sadrži hidroksipropilbetadeks, koji može biti pogodan za stvaranje kompleksa s drugim lijekovima, što može dovesti do povećane bioraspoloživosti takvog lijeka (osobito lijekova s niskom topljivošću, vidjeti dio 5.2).
English: What MAVENCLAD is and what it is used for What you need to know before you take MAVENCLAD How to take MAVENCLAD Possible side effects
Croatian: Što je MAVENCLAD i za što se koristi Što morate znati prije nego počnete uzimati MAVENCLAD Kako uzimati MAVENCLAD
English: The lymphocyte counts of more than 75% of patients returned to the normal range by week 144 from the first dose of cladribine (approximately 90 weeks after the last dose of cladribine).
Croatian: Broj limfocita u više od 75 % bolesnika vratio se u normalan raspon do 144. tjedna nakon prve doze kladribina (približno 90 tjedana nakon zadnje doze kladribina).
English: The observed embryolethal and teratogenic effects are consistent with the pharmacologic mechanisms of cladribine.
Croatian: Opaženi embrioletalni i teratogeni učinci bili su sukladni farmakološkim mehanizmima kladribina.
English: • An introduction to Mavenclad, reminding the prescriber to consider the Patient Guide while discussing Mavenclad treatment with the patient, to support the early identification of sign and symptoms of adverse reactions and their timely treatment;
Croatian: • Upoznavanje s lijekom Mavenclad, u kojem se podsjeća propisivača da ima na umu Vodič za bolesnike dok razgovara s bolesnikom o liječenju lijekom Mavenclad, kako bi se doprinjelo ranom prepoznavanju znakova i simptoma nuspojava i njihovog pravovremenog liječenja;
English: The safety and efficacy of MAVENCLAD in patients below the age of 18 years have not been established.
Croatian: Sigurnost i djelotvornost lijeka MAVENCLAD u bolesnika mlađih od 18 godina nisu ustanovljene.
English: In patients who require blood transfusion, irradiation of cellular blood components is recommended prior to administration to prevent transfusion-related graft-versus-host disease.
Croatian: U bolesnika kojima je potrebna transfuzija krvi, preporučuje se zračenje staničnih sastavnica krvi prije primjene kako bi se spriječila bolest presatka protiv primatelja povezana s transfuzijom.
English: Safety and efficacy of MAVENCLAD in combination with other disease-modifying treatments for MS have not been established.
Croatian: Sigurnost i djelotvornost lijeka MAVENCLAD u kombinaciji s drugim liječenjima koja mijenjaju tijek bolesti za MS nisu ustanovljene.
English: Cladribine did not affect the fertility of male mice, but observed testicular effects were reduced testicular weights and increased numbers of non-motile sperm.
Croatian: Kladribin nije utjecao na plodnost mužjaka miša, ali opaženi testikularni učinci bili su smanjena težina testisa i povećan broj nepokretnih spermija.
English: Table 2 shows how the total number of tablets per treatment week is distributed over the individual days.
Croatian: Tablica 2 prikazuje kako se ukupni broj tableta u tjednu liječenja raspodjeljuje po pojedinim danima.
English: The remaining patients were pre-treated with either interferon beta-1a, interferon beta-1b, glatiramer acetate or natalizumab.
Croatian: Preostali bolesnici bili su prethodno liječeni bilo interferonom beta-1a, interferonom beta-1b, glatiramer acetatom ili natalizumabom.
English: - If a tablet is left on a surface or if it breaks and fragments fall from the blister, the area must be thoroughly washed.
Croatian: - Ako se tableta ostavi na nekoj površini ili ako se razlomi i komadići ispadnu iz blistera, to se područje mora temeljito oprati.
English: The mechanism by which cladribine exerts its therapeutic effects in MS is not fully elucidated but its predominant effect on B and T lymphocytes is thought to interrupt the cascade of immune events central to MS.
Croatian: Mehanizam kojim kladribin postiže svoje terapijske učinke kod MS-a nije u potpunosti objašnjen, ali smatra se da njegov pretežni utjecaj na B i T limfocite prekida kaskadu glavnih imunoloških događaja kod MS-a.
English: What you need to know before you take MAVENCLAD
Croatian: Što morate znati prije nego počnete uzimati MAVENCLAD
English: Treatment with MAVENCLAD must be initiated and supervised by a physician experienced in the treatment of MS.
Croatian: Liječenje lijekom MAVENCLAD mora započeti i nadzirati liječnik s iskustvom u liječenju MS-a.
English: There is no indication that cladribine pharmacokinetics might change in a time-dependent fashion after repeated administration.
Croatian: Nema pokazatelja da bi se farmakokinetika kladribina mogla promijeniti na način ovisan o vremenu nakon ponovljene primjene.
English: Cladribine is a nucleoside analogue of deoxyadenosine.
Croatian: Kladribin je nukleozidni analog deoksiadenozina.
English: Relapsing-remitting MS
Croatian: Relapsno-remitirajući MS
English: Use of oral cladribine in patients weighing less than 40 kg has not been investigated.
Croatian: Primjena peroralnog kladribina u bolesnika tjelesne težine manje od 40 kg nije ispitana.
English: Inhibition of these enzymes or genetic polymorphisms (e.g. CYP2D6, CYP2C9 or CYP2C19) are not expected to result in clinically significant effects on cladribine pharmacokinetics or exposure.
Croatian: Ne očekuje se da će inhibicija ovih enzima ili genskih polimorfizama (npr. CYP2D6, CYP2C9 ili CYP2C19) rezultirati klinički značajnim učincima na farmakokinetiku kladribina ili izloženost kladribinu.
English: Other medicines and MAVENCLAD
Croatian: Drugi lijekovi i MAVENCLAD
English: The incidence of affected mouse foetuses in this study was in the same range of spontaneous incidence of amelia and phocomelia in this strain of mice.
Croatian: Incidencija tako zahvaćenih fetusa miša u ovom ispitivanju bila je u istom rasponu kao i spontana incidencija amelije i fokomelije u ovog soja miševa.
English: Cladribine is a prodrug that has to be phosphorylated intracellularly to become biologically active.
Croatian: Kladribin je prolijek koji mora biti fosforiliran unutar stanice da bi postao biološki aktivan.
English: What MAVENCLAD contains
Croatian: Što MAVENCLAD sadrži
English: There was no difference in annualised relapse rate between patients with relapsing-remitting MS and patients with secondary progressive MS with relapses.
Croatian: Nije bilo razlike u anualiziranoj stopi relapsa između bolesnika s relapsnoremitirajućim MS-om i bolesnika sa sekundarno progresivnim MS-om s relapsima.
English: Very rare (<1/10,000)
Croatian: Vrlo rijetko (< 1/10 000)
English: 110 and above
Croatian: 110 i više
English: A supportive study in patients treated with cladribine as an add-on to interferon-beta vs. placebo + interferon-beta also included a limited number of patients with secondary progressive MS (26 patients).
Croatian: Potporno ispitivanje u bolesnika liječenih kladribinom kao dodatnom terapijom uz interferon-beta naspram placeba + interferon-beta također je uključilo ograničeni broj bolesnika sa sekundarnim progresivnim MS-om (26 bolesnika).
English: In vivo clastogenicity in mice was detected at 10 mg/kg, which was the lowest dose tested.
Croatian: In vivo klastogenost u miševa bila je otkrivena pri dozi od 10 mg/kg, što je bila najniža ispitana doza.
English: Over two thirds of the study patients were treatment-naive for MS disease-modifying drugs (DMDs).
Croatian: Više od dvije trećine ispitanika prethodno nije bilo liječeno zbog MS-a lijekovima koji mijenjaju tijek bolesti (engl. disease-modifying drugs, DMD).
English: Dose in mg (number of 10 mg tablets) per treatment week kg
Croatian: Doza u mg (broj tableta od 10 mg) po tjednu liječenja kg
English: Example: If you forget to take the Day 3 dose and do not remember it until Day 4, take the Day 3 dose on Day 4, and extend the total number of days in the treatment week by 1 day.
Croatian: Primjer: Ako ste zaboravili uzeti dozu 3. dana i toga se sjetite tek 4. dana, uzmite 4. dan dozu koju ste trebali uzeti 3. dana i produžite ukupni broj dana u tom tjednu liječenja za 1 dan.
English: MAVENCLAD is indicated for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features (see section 5.1).
Croatian: MAVENCLAD je indiciran za liječenje odraslih bolesnika s visoko aktivnom relapsnom multiplom sklerozom (MS), definiranom na temelju kliničkih ili slikovnih značajki (vidjeti dio 5.1).
English: Take the missed dose on that day.
Croatian: Uzmite propuštenu dozu tog istog dana.
English: Patients should be advised to undertake standard cancer screening after Mavenclad treatment;
Croatian: bolesnicima treba savjetovati da obave standardne probire na rak nakon liječenja lijekom Mavenclad;
English: The primary apoptosis-inducing mechanism of action of Cd-ATP has direct and indirect actions on DNA synthesis and mitochondrial function.
Croatian: Primarni mehanizam djelovanja Cd-ATP-a koji dovodi do apoptoze izravno i neizravno djeluje na sintezu DNK i funkciju mitohondrija.
English: Contraception
Croatian: Kontracepcija
English: Changing treatments
Croatian: Promjena liječenja
English: Caution is recommended when MAVENCLAD is used in elderly patients, taking into account the potential greater frequency of decreased hepatic or renal function, concomitant diseases and other medicinal therapies.
Croatian: Preporučuje se oprez kad se MAVENCLAD primjenjuje u starijih bolesnika, s obzirom na moguću veću učestalost smanjene funkcije jetre ili bubrega, istovremenih bolesti i terapija drugim lijekovima.
English: A potential additive effect on the immune system should also be considered when such medicinal products are used after treatment with MAVENCLAD (see section 4.5).
Croatian: Također je potrebno uzeti u obzir mogući aditivni učinak na imunološki sustav kad se takvi lijekovi primjenjuju nakon liječenja lijekom MAVENCLAD (vidjeti dio 4.5).
English: • Important potential risks Progressive multifocal leukoencephalopathy (PML), opportunistic infections (other than PML and tuberculosis) and severe infections, to ensure awareness of signs and symptoms suggestive of these risks; Malignancies, to raise awareness on this risk because: a.
Croatian: • Važni mogući rizici Progresivna multifokalna leukoencefalopatija (PML), oportunističke infekcije (osim PML-a i tuberkuloze) i teške infekcije, kako bi se osigurala svijest o znakovima i simptomima koji bi mogli ukazivati na te rizke; Zloćudne bolesti, kako bi se podigla svijest o ovom riziku jer: a.
English: Pregnancy and breast-feeding (see section 4.6).
Croatian: Trudnoća i dojenje (vidjeti dio 4.6).
English: White, round, biconvex tablets of 8.5 mm diameter, engraved with 'C' on one side and '10' on the other side.
Croatian: Bijele, okrugle, bikonveksne tablete promjera 8,5 mm, s utisnutim „C” na jednoj strani i „10” na drugoj strani.
English: What MAVENCLAD looks like and contents of the pack
Croatian: Kako MAVENCLAD izgleda i sadržaj pakiranja
English: The magnitude of the effect in reducing the frequency of relapses and slowing disability progression in patients receiving the 3.5 mg/kg dose over 2 years was maintained in years 3 and 4 (see section 4.2).
Croatian: Značaj učinka na smanjenje učestalosti relapsa i usporavanje napredovanja onesposobljenosti u bolesnika koji su primili dozu od 3,5 mg/kg tijekom 2 godine održana je 3. i 4. godine (vidjeti dio 4.2).
English: Although the clinical relevance of such interactions is unknown, it is recommended that coadministration of potent ENT1, CNT3 or BCRP inhibitors be avoided during the 4- to 5-day cladribine treatment.
Croatian: Iako klinička važnost takvih interakcija nije poznata, preporučuje se izbjegavati istodobnu primjenu jakih inhibitora ENT1, CNT3 ili BCRP tijekom 4 do 5 dana liječenja kladribinom.
English: 2 Push and hold hooks
Croatian: 2 Pritisnite i držite kvačice.
English: th percentile for disability progression was reached between 16 and 23 weeks, while for the cladribine groups it was not reached during the entire study.
Croatian: Za placebo je 10. percentila za napredovanje onesposobljenosti bila postignuta između 16. i 23. tjedna, dok u skupinama koje su primale kladribin nije bila postignuta tijekom cijelog trajanja ispitivanja.
English: MAVENCLAD contains hydroxypropylbetadex that may interact with other medicines in your stomach.
Croatian: MAVENCLAD sadrži hidroksipropilbetadeks koji može ući u interakciju s drugim lijekovima u želucu.
English: The distribution of cladribine across biological membranes is facilitated by various transport proteins, including ENT1, CNT3 and BCRP.
Croatian: Raspodjelu kladribina kroz biološke membrane olakšavaju razni prijenosni proteini, uključujući ENT1, CNT3 i BCRP.
English: To decrease the risk for severe lymphopenia, lymphocyte counts must be determined before, during and after cladribine treatment (see section 4.4) and strict criteria for initiating and continuing cladribine treatment must be followed (see section 4.2).
Croatian: Da bi se smanjio rizik od teške limfopenije, broj limfocita mora se odrediti prije, tijekom i nakon liječenja kladribinom (vidjeti dio 4.4) i moraju se slijediti strogi kriteriji za započinjanje i nastavak liječenja kladribinom (vidjeti dio 4.2).
English: Treatment with MAVENCLAD has been shown to reduce flare-ups of symptoms and to slow down progression of disability.
Croatian: Pokazalo se da liječenje lijekom MAVENCLAD smanjuje razbuktavanje simptoma i usporava napredovanje onesposobljenosti.
English: Patients treated with MAVENCLAD should be advised to follow standard cancer screening guidelines.
Croatian: Bolesnicima liječenima lijekom MAVENCLAD treba savjetovati da se pridržavaju standarnih smjernica za probir na rak.
English: If you change from MAVENCLAD to other MS treatments, talk to your doctor.
Croatian: Ako prelazite s lijeka MAVENCLAD na druge lijekove za MS, obratite se liječniku.
English: For treatment decisions based on the patient's lymphocyte counts, see section 4.2 and subsection 'Infections' below.
Croatian: Za odluke o liječenju s obzirom na broj lifmocita u bolesnika, vidjeti dio 4.2 i odlomak „Infekcije” niže.
English: Table 1 Dose of MAVENCLAD per treatment week by patient weight in each treatment year
Croatian: Tablica 1 Doza lijeka MAVENCLAD po tjednu liječenja prema tjelesnoj težini bolesnika u svakoj godini liječenja
English: It is recommended that the daily cladribine doses in each treatment week be taken at intervals of 24 hours at approximately the same time each day.
Croatian: U svakom tjednu liječenja, preporučuje se dnevne doze kladribina uzimati u razmaku od 24 sata, u približno isto vrijeme svakog dana.
English: Blood transfusions
Croatian: Transfuzije krvi
English: In vitro studies indicate that cladribine efflux is only minimally P-gp related.
Croatian: In vitro ispitivanja pokazuju da je efluks kladribina samo minimalno povezan s P-gp-om.
English: Other symptoms may be headache, burning, tingling, numbness or itchiness of the skin in the affected area, feeling generally unwell or feverish in the early stages of infection.
Croatian: Drugi simptomi mogu biti glavobolja, žarenje, trnci, utrnulost ili svrbež kože na zahvaćenom području, opće loše osjećanje i vrućica u ranim fazama infekcije.
English: Although PML has not been observed with MAVENCLAD, as a precaution, you may have a head MRI (magnetic resonance imaging) before you start treatment.
Croatian: Iako PML nije opažen uz MAVENCLAD, kao mjeru opreza, prije nego što započnete s liječenjem možete napraviti snimanje glave magnetskom rezonancijom (MR).
English: If a tablet is left on a surface, or if a broken or fragmented tablet is released from the blister, the area must be thoroughly washed.
Croatian: Ako se tableta ostavi na nekoj površini, ili ako se iz blistera izvadi slomljena ili razlomljena tableta, to se područje mora temeljito oprati.
English: Lymphopenia is known to be dosedependent (see sections 4.4 and 4.8).
Croatian: Poznato je da je limfopenija ovisna o dozi (vidjeti dijelove 4.4 i 4.8).
English: - if you have moderate or severe kidney problems.
Croatian: - ako imate umjerene ili teške bubrežne tegobe.
English: Cladribine has the potential to penetrate the blood brain barrier.
Croatian: Kladribin može prodrijeti kroz krvno-moždanu barijeru.
English: Cladribine did not induce gene mutation in bacteria or mammalian cells, but it was clastogenic causing chromosomal damage in mammalian cells in vitro at a concentration which was 17-fold above the expected clinical Cmax.
Croatian: Kladribin nije izazvao genske mutacije u bakterijama niti u stanicama sisavaca, ali je bio klastogen, uzrokujući kromosomska oštećenja u stanicama sisavaca in vitro u koncentraciji koja je bila 17 puta veća od očekivanog kliničkog Cmax.
English: In this extension study, 806 patients received either placebo or a cumulative dose of cladribine 3.5 mg/kg (in a regimen similar to that used in CLARITY) over the 96-week study period.
Croatian: U tom produžetku ispitivanja, 806 bolesnika primilo je placebo ili kumulativnu dozu kladribina od 3,5 mg/kg (u režimu sličnom onom koji se koristio u ispitivanju CLARITY) tijekom 96-tjedana ispitivanja.
English: Subsequent phosphorylation of cladribine to its active triphosphate form, 2-chlorodeoxyadenosine triphosphate (Cd-ATP), is particularly efficiently achieved in lymphocytes, due to their constitutively high deoxycytidine kinase (DCK) and relatively low 5'-nucleotidase (5'-NTase) levels.
Croatian: Slijedi fosforilacija kladribina do njegovog aktivnog trifosfatnog oblika, 2-klorodeoksiadenozin-trifosfata (Cd-ATP), koja se osobito učinkovito odvija u limfocitima, zbog toga što prirodno sadrže višu razinu deoksicitidin kinaze (DCK) i relativno nisku razinu 5'-nukleotidaze (5'-NTaze).
English: DCK is the rate limiting enzyme for conversion of the cladribine prodrug into its active triphosphate form, leading to selective depletion of dividing and non-dividing T and B cells.
Croatian: DCK je enzim koji ograničava brzinu konverzije prolijeka kladribina u njegov aktivni trifosfatni oblik, što dovodi do selektivne deplecije i onih T i B stanica koje se dijele i onih koje se ne dijele.
English: After oral administration of cladribine across a dose range from 3 to 20 mg, Cmax and AUC increased in a dose-proportional fashion, suggesting that absorption is not affected by rate- or capacity-limited processes up to a 20 mg oral dose.
Croatian: Nakon peroralne primjene kladribina u rasponu doza od 3 do 20 mg, Cmax i AUC povećavali su se proporcionalno dozi, što ukazuje na to da procesi ograničene brzine ili kapaciteta ne utječu na apsorpciju peroralne doze do 20 mg.